Last reviewed · How we verify
Bacillus Coagulans Tablets
Bacillus Coagulans Tablets, marketed by Xijing Hospital of Digestive Diseases, hold a niche position in the digestive health market. The key composition patent, set to expire in 2028, provides a significant barrier to entry for potential generic competitors. However, the lack of a clear primary indication and revenue data poses a strategic risk, potentially limiting market expansion and investment interest.
At a glance
| Generic name | Bacillus Coagulans Tablets |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy (PHASE4)
- Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets (PHASE4)
- A Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals (PHASE1)
- Estromineral Serena Plus and Symptomatic Menopause (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacillus Coagulans Tablets CI brief — competitive landscape report
- Bacillus Coagulans Tablets updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI